BIO-TECHNE Corp vs United States Natural Gas Fund — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while United States Natural Gas Fund trades at $10.78 (market cap $522.93M). The key difference: BIO-TECHNE Corp is far larger — about 21.7× United States Natural Gas Fund's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while United States Natural Gas Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and United States Natural Gas Fund for 22 Days on average.
| TECH | UNG | |
|---|---|---|
Market Cap | $11.37B | $522.93M |
Volume | 3,153,511 | 33,973,188 |
Sector | Health | Commodities - Energy |
52-Week High | $72.61 | $16.90 |
52-Week Low | $43.31 | $9.63 |
Typical Hold Time | 63 Days | 22 Days |
Enterprise Value | $11.40B | — |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
UNG trades at $11.03, up 2.7% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported a net income of $65.15 million in 2024, though revenue was $0.00, and maintains a strong balance sheet with total assets of $790.02 million and minimal liabilities. Recent news highlights volatility in natural gas markets due to geopolitical tensions and record U.S. production.
The outlook for UNG is mixed, with bullish technicals and solid profitability offset by revenue uncertainty and market risks. Key opportunities include potential price support from geopolitical events, while risks involve natural gas price fluctuations and high production levels pressuring margins.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →